Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers
• Improve the solubility and consequently enhance the oral bioavailability of progesterone (P). • Use a suitable co-former to convert the parent compound progesterone into a co-crystal. • Using solution crystallization technology in the stoichiometric ratio of 1: 4 and 1: 2. • The results show that...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Yunxia, Yang [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting - 2011, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:585 ; year:2022 ; day:1 ; month:05 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jcrysgro.2022.126601 |
|---|
| Katalog-ID: |
ELV057017220 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV057017220 | ||
| 003 | DE-627 | ||
| 005 | 20230624235852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220808s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcrysgro.2022.126601 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001697.pica |
| 035 | |a (DE-627)ELV057017220 | ||
| 035 | |a (ELSEVIER)S0022-0248(22)00089-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 570 |a 540 |q VZ |
| 100 | 1 | |a Yunxia, Yang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers |
| 264 | 1 | |c 2022 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Improve the solubility and consequently enhance the oral bioavailability of progesterone (P). • Use a suitable co-former to convert the parent compound progesterone into a co-crystal. • Using solution crystallization technology in the stoichiometric ratio of 1: 4 and 1: 2. • The results show that the co-crystal can improve the solubility of progesterone in water. • Pharmaceutical cocrystal can solve the problem of poorly soluble APIs. | ||
| 650 | 7 | |a A1. Poor water solubility |2 Elsevier | |
| 650 | 7 | |a A2. Progesterone |2 Elsevier | |
| 650 | 7 | |a A1. Dissolution |2 Elsevier | |
| 650 | 7 | |a A2. Pharmaceutical cocrystal |2 Elsevier | |
| 650 | 7 | |a A2. Cocrystal |2 Elsevier | |
| 650 | 7 | |a A1. Solubility |2 Elsevier | |
| 650 | 7 | |a A1. Oral bioavailability |2 Elsevier | |
| 700 | 1 | |a Huihui, Niu |4 oth | |
| 700 | 1 | |a Shiying, Xia |4 oth | |
| 700 | 1 | |a yingwa, Guo |4 oth | |
| 700 | 1 | |a Xiangxiang, Wu |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |t The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting |d 2011 |g Amsterdam [u.a.] |w (DE-627)ELV010662650 |
| 773 | 1 | 8 | |g volume:585 |g year:2022 |g day:1 |g month:05 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jcrysgro.2022.126601 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_105 | ||
| 951 | |a AR | ||
| 952 | |d 585 |j 2022 |b 1 |c 0501 |h 0 | ||
| author_variant |
y y yy |
|---|---|
| matchkey_str |
yunxiayanghuihuiniushiyingxiayingwaguoxi:2022----:ouiiyndsouinaefrgseoeorsassn4looeziaiadh |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
10.1016/j.jcrysgro.2022.126601 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001697.pica (DE-627)ELV057017220 (ELSEVIER)S0022-0248(22)00089-6 DE-627 ger DE-627 rakwb eng 610 VZ 570 540 VZ Yunxia, Yang verfasserin aut Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Improve the solubility and consequently enhance the oral bioavailability of progesterone (P). • Use a suitable co-former to convert the parent compound progesterone into a co-crystal. • Using solution crystallization technology in the stoichiometric ratio of 1: 4 and 1: 2. • The results show that the co-crystal can improve the solubility of progesterone in water. • Pharmaceutical cocrystal can solve the problem of poorly soluble APIs. A1. Poor water solubility Elsevier A2. Progesterone Elsevier A1. Dissolution Elsevier A2. Pharmaceutical cocrystal Elsevier A2. Cocrystal Elsevier A1. Solubility Elsevier A1. Oral bioavailability Elsevier Huihui, Niu oth Shiying, Xia oth yingwa, Guo oth Xiangxiang, Wu oth Enthalten in Elsevier The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting 2011 Amsterdam [u.a.] (DE-627)ELV010662650 volume:585 year:2022 day:1 month:05 pages:0 https://doi.org/10.1016/j.jcrysgro.2022.126601 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_22 GBV_ILN_40 GBV_ILN_105 AR 585 2022 1 0501 0 |
| spelling |
10.1016/j.jcrysgro.2022.126601 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001697.pica (DE-627)ELV057017220 (ELSEVIER)S0022-0248(22)00089-6 DE-627 ger DE-627 rakwb eng 610 VZ 570 540 VZ Yunxia, Yang verfasserin aut Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Improve the solubility and consequently enhance the oral bioavailability of progesterone (P). • Use a suitable co-former to convert the parent compound progesterone into a co-crystal. • Using solution crystallization technology in the stoichiometric ratio of 1: 4 and 1: 2. • The results show that the co-crystal can improve the solubility of progesterone in water. • Pharmaceutical cocrystal can solve the problem of poorly soluble APIs. A1. Poor water solubility Elsevier A2. Progesterone Elsevier A1. Dissolution Elsevier A2. Pharmaceutical cocrystal Elsevier A2. Cocrystal Elsevier A1. Solubility Elsevier A1. Oral bioavailability Elsevier Huihui, Niu oth Shiying, Xia oth yingwa, Guo oth Xiangxiang, Wu oth Enthalten in Elsevier The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting 2011 Amsterdam [u.a.] (DE-627)ELV010662650 volume:585 year:2022 day:1 month:05 pages:0 https://doi.org/10.1016/j.jcrysgro.2022.126601 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_22 GBV_ILN_40 GBV_ILN_105 AR 585 2022 1 0501 0 |
| allfields_unstemmed |
10.1016/j.jcrysgro.2022.126601 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001697.pica (DE-627)ELV057017220 (ELSEVIER)S0022-0248(22)00089-6 DE-627 ger DE-627 rakwb eng 610 VZ 570 540 VZ Yunxia, Yang verfasserin aut Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Improve the solubility and consequently enhance the oral bioavailability of progesterone (P). • Use a suitable co-former to convert the parent compound progesterone into a co-crystal. • Using solution crystallization technology in the stoichiometric ratio of 1: 4 and 1: 2. • The results show that the co-crystal can improve the solubility of progesterone in water. • Pharmaceutical cocrystal can solve the problem of poorly soluble APIs. A1. Poor water solubility Elsevier A2. Progesterone Elsevier A1. Dissolution Elsevier A2. Pharmaceutical cocrystal Elsevier A2. Cocrystal Elsevier A1. Solubility Elsevier A1. Oral bioavailability Elsevier Huihui, Niu oth Shiying, Xia oth yingwa, Guo oth Xiangxiang, Wu oth Enthalten in Elsevier The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting 2011 Amsterdam [u.a.] (DE-627)ELV010662650 volume:585 year:2022 day:1 month:05 pages:0 https://doi.org/10.1016/j.jcrysgro.2022.126601 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_22 GBV_ILN_40 GBV_ILN_105 AR 585 2022 1 0501 0 |
| allfieldsGer |
10.1016/j.jcrysgro.2022.126601 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001697.pica (DE-627)ELV057017220 (ELSEVIER)S0022-0248(22)00089-6 DE-627 ger DE-627 rakwb eng 610 VZ 570 540 VZ Yunxia, Yang verfasserin aut Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Improve the solubility and consequently enhance the oral bioavailability of progesterone (P). • Use a suitable co-former to convert the parent compound progesterone into a co-crystal. • Using solution crystallization technology in the stoichiometric ratio of 1: 4 and 1: 2. • The results show that the co-crystal can improve the solubility of progesterone in water. • Pharmaceutical cocrystal can solve the problem of poorly soluble APIs. A1. Poor water solubility Elsevier A2. Progesterone Elsevier A1. Dissolution Elsevier A2. Pharmaceutical cocrystal Elsevier A2. Cocrystal Elsevier A1. Solubility Elsevier A1. Oral bioavailability Elsevier Huihui, Niu oth Shiying, Xia oth yingwa, Guo oth Xiangxiang, Wu oth Enthalten in Elsevier The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting 2011 Amsterdam [u.a.] (DE-627)ELV010662650 volume:585 year:2022 day:1 month:05 pages:0 https://doi.org/10.1016/j.jcrysgro.2022.126601 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_22 GBV_ILN_40 GBV_ILN_105 AR 585 2022 1 0501 0 |
| allfieldsSound |
10.1016/j.jcrysgro.2022.126601 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001697.pica (DE-627)ELV057017220 (ELSEVIER)S0022-0248(22)00089-6 DE-627 ger DE-627 rakwb eng 610 VZ 570 540 VZ Yunxia, Yang verfasserin aut Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Improve the solubility and consequently enhance the oral bioavailability of progesterone (P). • Use a suitable co-former to convert the parent compound progesterone into a co-crystal. • Using solution crystallization technology in the stoichiometric ratio of 1: 4 and 1: 2. • The results show that the co-crystal can improve the solubility of progesterone in water. • Pharmaceutical cocrystal can solve the problem of poorly soluble APIs. A1. Poor water solubility Elsevier A2. Progesterone Elsevier A1. Dissolution Elsevier A2. Pharmaceutical cocrystal Elsevier A2. Cocrystal Elsevier A1. Solubility Elsevier A1. Oral bioavailability Elsevier Huihui, Niu oth Shiying, Xia oth yingwa, Guo oth Xiangxiang, Wu oth Enthalten in Elsevier The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting 2011 Amsterdam [u.a.] (DE-627)ELV010662650 volume:585 year:2022 day:1 month:05 pages:0 https://doi.org/10.1016/j.jcrysgro.2022.126601 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_22 GBV_ILN_40 GBV_ILN_105 AR 585 2022 1 0501 0 |
| language |
English |
| source |
Enthalten in The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting Amsterdam [u.a.] volume:585 year:2022 day:1 month:05 pages:0 |
| sourceStr |
Enthalten in The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting Amsterdam [u.a.] volume:585 year:2022 day:1 month:05 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
A1. Poor water solubility A2. Progesterone A1. Dissolution A2. Pharmaceutical cocrystal A2. Cocrystal A1. Solubility A1. Oral bioavailability |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting |
| authorswithroles_txt_mv |
Yunxia, Yang @@aut@@ Huihui, Niu @@oth@@ Shiying, Xia @@oth@@ yingwa, Guo @@oth@@ Xiangxiang, Wu @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV010662650 |
| dewey-sort |
3610 |
| id |
ELV057017220 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV057017220</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624235852.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcrysgro.2022.126601</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001697.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV057017220</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0022-0248(22)00089-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yunxia, Yang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Improve the solubility and consequently enhance the oral bioavailability of progesterone (P). • Use a suitable co-former to convert the parent compound progesterone into a co-crystal. • Using solution crystallization technology in the stoichiometric ratio of 1: 4 and 1: 2. • The results show that the co-crystal can improve the solubility of progesterone in water. • Pharmaceutical cocrystal can solve the problem of poorly soluble APIs.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A1. Poor water solubility</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A2. Progesterone</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A1. Dissolution</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A2. Pharmaceutical cocrystal</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A2. Cocrystal</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A1. Solubility</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A1. Oral bioavailability</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huihui, Niu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shiying, Xia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">yingwa, Guo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xiangxiang, Wu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting</subfield><subfield code="d">2011</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV010662650</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:585</subfield><subfield code="g">year:2022</subfield><subfield code="g">day:1</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jcrysgro.2022.126601</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">585</subfield><subfield code="j">2022</subfield><subfield code="b">1</subfield><subfield code="c">0501</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Yunxia, Yang |
| spellingShingle |
Yunxia, Yang ddc 610 ddc 570 Elsevier A1. Poor water solubility Elsevier A2. Progesterone Elsevier A1. Dissolution Elsevier A2. Pharmaceutical cocrystal Elsevier A2. Cocrystal Elsevier A1. Solubility Elsevier A1. Oral bioavailability Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers |
| authorStr |
Yunxia, Yang |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV010662650 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 570 540 VZ Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers A1. Poor water solubility Elsevier A2. Progesterone Elsevier A1. Dissolution Elsevier A2. Pharmaceutical cocrystal Elsevier A2. Cocrystal Elsevier A1. Solubility Elsevier A1. Oral bioavailability Elsevier |
| topic |
ddc 610 ddc 570 Elsevier A1. Poor water solubility Elsevier A2. Progesterone Elsevier A1. Dissolution Elsevier A2. Pharmaceutical cocrystal Elsevier A2. Cocrystal Elsevier A1. Solubility Elsevier A1. Oral bioavailability |
| topic_unstemmed |
ddc 610 ddc 570 Elsevier A1. Poor water solubility Elsevier A2. Progesterone Elsevier A1. Dissolution Elsevier A2. Pharmaceutical cocrystal Elsevier A2. Cocrystal Elsevier A1. Solubility Elsevier A1. Oral bioavailability |
| topic_browse |
ddc 610 ddc 570 Elsevier A1. Poor water solubility Elsevier A2. Progesterone Elsevier A1. Dissolution Elsevier A2. Pharmaceutical cocrystal Elsevier A2. Cocrystal Elsevier A1. Solubility Elsevier A1. Oral bioavailability |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
n h nh x s xs g y gy w x wx |
| hierarchy_parent_title |
The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting |
| hierarchy_parent_id |
ELV010662650 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV010662650 |
| title |
Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers |
| ctrlnum |
(DE-627)ELV057017220 (ELSEVIER)S0022-0248(22)00089-6 |
| title_full |
Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers |
| author_sort |
Yunxia, Yang |
| journal |
The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting |
| journalStr |
The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Yunxia, Yang |
| container_volume |
585 |
| class |
610 VZ 570 540 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Yunxia, Yang |
| doi_str_mv |
10.1016/j.jcrysgro.2022.126601 |
| dewey-full |
610 570 540 |
| title_sort |
solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers |
| title_auth |
Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers |
| abstract |
• Improve the solubility and consequently enhance the oral bioavailability of progesterone (P). • Use a suitable co-former to convert the parent compound progesterone into a co-crystal. • Using solution crystallization technology in the stoichiometric ratio of 1: 4 and 1: 2. • The results show that the co-crystal can improve the solubility of progesterone in water. • Pharmaceutical cocrystal can solve the problem of poorly soluble APIs. |
| abstractGer |
• Improve the solubility and consequently enhance the oral bioavailability of progesterone (P). • Use a suitable co-former to convert the parent compound progesterone into a co-crystal. • Using solution crystallization technology in the stoichiometric ratio of 1: 4 and 1: 2. • The results show that the co-crystal can improve the solubility of progesterone in water. • Pharmaceutical cocrystal can solve the problem of poorly soluble APIs. |
| abstract_unstemmed |
• Improve the solubility and consequently enhance the oral bioavailability of progesterone (P). • Use a suitable co-former to convert the parent compound progesterone into a co-crystal. • Using solution crystallization technology in the stoichiometric ratio of 1: 4 and 1: 2. • The results show that the co-crystal can improve the solubility of progesterone in water. • Pharmaceutical cocrystal can solve the problem of poorly soluble APIs. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_22 GBV_ILN_40 GBV_ILN_105 |
| title_short |
Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers |
| url |
https://doi.org/10.1016/j.jcrysgro.2022.126601 |
| remote_bool |
true |
| author2 |
Huihui, Niu Shiying, Xia yingwa, Guo Xiangxiang, Wu |
| author2Str |
Huihui, Niu Shiying, Xia yingwa, Guo Xiangxiang, Wu |
| ppnlink |
ELV010662650 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.jcrysgro.2022.126601 |
| up_date |
2024-07-06T22:02:52.622Z |
| _version_ |
1803868829251534848 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV057017220</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624235852.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcrysgro.2022.126601</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001697.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV057017220</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0022-0248(22)00089-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yunxia, Yang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Solubility and dissolution rate of progesterone cocrystals using 4-fluorobenzoic acid and 2-hydroxy-6-naphthoic acid as coformers</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Improve the solubility and consequently enhance the oral bioavailability of progesterone (P). • Use a suitable co-former to convert the parent compound progesterone into a co-crystal. • Using solution crystallization technology in the stoichiometric ratio of 1: 4 and 1: 2. • The results show that the co-crystal can improve the solubility of progesterone in water. • Pharmaceutical cocrystal can solve the problem of poorly soluble APIs.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A1. Poor water solubility</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A2. Progesterone</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A1. Dissolution</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A2. Pharmaceutical cocrystal</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A2. Cocrystal</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A1. Solubility</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">A1. Oral bioavailability</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huihui, Niu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shiying, Xia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">yingwa, Guo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xiangxiang, Wu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">The mental health of doctor-shoppers: Experience from a patient-led fee-for-service primary care setting</subfield><subfield code="d">2011</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV010662650</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:585</subfield><subfield code="g">year:2022</subfield><subfield code="g">day:1</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jcrysgro.2022.126601</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">585</subfield><subfield code="j">2022</subfield><subfield code="b">1</subfield><subfield code="c">0501</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.3995314 |